| 生物活性 | |||
|---|---|---|---|
| 靶点 |
|
||
| 描述 | AC480 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, > 100-fold to VEGFR2, c-Kit, Lck, MET etc. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00093730 | Unspecified Adult Solid Tumor,... 展开 >> Protocol Specific 收起 << | Phase 1 | Completed | - | United States, California ... 展开 >> Jonsson Comprehensive Cancer Center at UCLA Los Angeles, California, United States, 90095-1781 收起 << |
| NCT00207012 | HER2 or EGFR Expressing Advanc... 展开 >>ed Solid Malignancies 收起 << | Phase 1 | Completed | - | France ... 展开 >> Local Institution Villejuif Cedex, France Spain Local Institution Barcelona, Spain 收起 << |
| NCT00095537 | Cancer Metast... 展开 >>ases 收起 << | Phase 1 | Completed | - | United States, Arizona ... 展开 >> Local Institution Scottsdale, Arizona, United States Local Institution Tucson, Arizona, United States United States, California Local Institution Los Angeles, California, United States 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.88mL 0.38mL 0.19mL |
9.42mL 1.88mL 0.94mL |
18.85mL 3.77mL 1.88mL |
| 参考文献 |
|---|